Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/01/2003CA2498591A1 Immunotherapy for reversing immune suppression
05/01/2003CA2466813A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003CA2465261A1 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
05/01/2003CA2464981A1 Quinoline compound
05/01/2003CA2464976A1 Superfine aqueous dispersion of noble metal for head massage
05/01/2003CA2464943A1 Acarbose purification process
05/01/2003CA2464795A1 Thymosin augmentation of genetic immunization
05/01/2003CA2464790A1 Treatment of acute myeloid leukemia with indolinone compounds
05/01/2003CA2464593A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003CA2464460A1 In vitro micro-organs, and uses related thereto
05/01/2003CA2464417A1 Promoters to control cell differentiation
05/01/2003CA2464394A1 Methods and compositions for inducing tumor-specific cytotoxicity
05/01/2003CA2464349A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003CA2464311A1 Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
05/01/2003CA2464277A1 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
05/01/2003CA2464271A1 Integrin targeting compounds
05/01/2003CA2464261A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003CA2464256A1 Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents
05/01/2003CA2464254A1 Inhibitors of post-proline cleaving proteases
05/01/2003CA2464239A1 Psma antibodies and protein multimers
05/01/2003CA2464111A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003CA2464085A1 A combination product comprising melagatran and dexamethasone
05/01/2003CA2463975A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
05/01/2003CA2463960A1 Transient immortalization
05/01/2003CA2463923A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same
05/01/2003CA2463902A1 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003CA2463803A1 Biphasic mixtures of glp-1 and insulin
05/01/2003CA2463311A1 Androgen receptor modulators and methods of use thereof
05/01/2003CA2463309A1 Sterile, breathable patch for treating wound pain
05/01/2003CA2463226A1 Acetic acid derivatives
05/01/2003CA2463101A1 Azole derivatives and pharmaceutical compositions containing them
05/01/2003CA2463043A1 Combination of liponic acid and glutamine in food and pharmaceutical products
05/01/2003CA2462250A1 Antidiabetic 2-substituted-5'-o- (1-boranotriphosphate) adenosine derivatives
05/01/2003CA2462163A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003CA2461545A1 Drugs comprising combination of triazaspiro¬5,5|undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor
05/01/2003CA2461181A1 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003CA2461159A1 Imidazopyridine compounds as 5-ht4 receptor modulators
05/01/2003CA2461085A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
05/01/2003CA2460665A1 Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing them and their applications
05/01/2003CA2458542A1 Enzyme inhibitors for inactivating allergens
04/2003
04/30/2003CN1414971A Depsipeptide and congeners thereof for use as immunosuppressants
04/30/2003CN1414963A Novel heteroary derivatives, their preparation and use
04/30/2003CN1414961A Substituted oximes and hydrazones as neurokinin antagonists
04/30/2003CN1414960A Substituted piperidines, medicaments containing these compounds, and methods for production thereof
04/30/2003CN1414954A Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof
04/30/2003CN1414953A Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and 5-hydroxytryptamine
04/30/2003CN1414952A Heterocyclic compounds having sulfonic acid
04/30/2003CN1414865A 癌症的治疗 Treatment of cancer
04/30/2003CN1414858A Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound
04/30/2003CN1414854A Phosphonate compounds
04/30/2003CN1414853A Oral mucosal dosage forms of apomorphine
04/30/2003CN1414852A Novel composition and use thereof
04/30/2003CN1414849A Carboxylic acid amides, medicaments containing these compounds and the use and preparation thereof
04/30/2003CN1414848A Prevention of plaque rupure by ACAT inhibitors
04/30/2003CN1413723A Method for extracting medicine from bluish dogbane
04/30/2003CN1413615A Tongmailing pill and its preparation method
04/30/2003CN1413605A Soft capsule capable of removing human peculliar smell
04/30/2003CN1107068C 2-amino-7-(1-substituted-2-hyroxyethyl)-3.5-diphydro-pyrrolo (3,2-D) pyrimidine-4-ones
04/30/2003CN1107061C Chemotaxis cell factor receptor-3 receptor antagonists
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106842C Usage of glutathione accelerator in preparating medicine for treating macular degeneration
04/30/2003CN1106840C Naringin and naringenin as 3-hydroxyl-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor
04/29/2003USRE38103 Preferential, nontoxic oxidoreductase inhibitors such as 5-Methanesulfonamido-6-(2,4-difluorophenylthio)-1-indanone administered for prophylaxis of gastrointestinal disorders
04/29/2003USRE38102 Use of a pyridazinone derivative
04/29/2003US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery
04/29/2003US6555689 Intermediates useful for the preparation of antihistaminic piperidine derivatives
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555583 Therapies for treating pulmonary diseases
04/29/2003US6555582 Eye treatments using synthetic thyroid hormone compositions
04/29/2003US6555578 Thyromimetic antiobesity agents
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555569 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
04/29/2003US6555562 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders
04/29/2003US6555558 Oral dosage self-emulsifying formulations of pyranone protease inhibitors
04/29/2003US6555557 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
04/29/2003US6555548 Administering therapeutically effective amount of active agent selected from the group consisting of a heterocyclic amine-type compound, a substituted phenylazacycloalkane-type compound, and a cabergoline-type compound, and their salts
04/29/2003US6555546 Use of 5HT3 antagonists for promoting intestinal lavage
04/29/2003US6555545 Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents
04/29/2003US6555543 Inhibiting the effects of platelet activating factor (PAF).
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555540 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
04/29/2003US6555539 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
04/29/2003US6555537 Piperazine derivatives and their use as anti-inflammatory agents
04/29/2003US6555535 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
04/29/2003US6555530 Administering a mixture of selective estrogen receptor modulators (SERMs), or estrogens with delta-gonadien-21-ol-3,20-diones of given formula
04/29/2003US6555528 Protease inhibitor
04/29/2003US6555527 Hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng
04/29/2003US6555520 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and immunologicval disorders
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555352 Peptide for use in human therapeutics and diagnostic compositions
04/29/2003US6555339 Altering human G protein-coupled receptors (GPCRs) by point mutation; use in drug screening
04/29/2003CA2258502C Modified factor viii
04/29/2003CA2227513C New ellipticine derivatives, their preparation process and the pharmaceutical compositions containing them
04/29/2003CA2181172C Storage-stable prostaglandin compositions
04/29/2003CA2134347C Thiazole or imidazole derivatives as maillard reaction inhibitors
04/24/2003WO2003034063A1 Method of screening remedy for atrial fibrillation
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033674A2 Human antibodies that have mn binding and cell adhesion-neutralizing activity
04/24/2003WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
04/24/2003WO2003033670A2 Method for preparation of single chain antibodies
1 ... 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 ... 1564